Highlights Aditxt, Inc.

Equities

ADTX

US0070256047

Market Closed - Nasdaq Other stock markets 02:00:00 26/06/2024 am IST			5-day change	1st Jan Change
1.436 ^USD	+1.84%		-0.28%	-78.34%

12/06	Aditxt, Inc. Announces Default Due to Failure to Repay the Balance on Maturity Date	CI
24/05	Aditxt, Inc. announced that it has received $0.775 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Appili Therapeutics To be Acquired by Aditxt, Inc.	02/04	MT
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
Aditxt's Pearsanta Unit Selected as Backup Bidder to Acquire Lucira Health's Assets	17/23/17	MT
Aditxt Says Unit Pearsanta Submitted Bid to Acquire All of Lucira Health Assets	17/23/17	CI
Aditxt, Inc. Announces the Formation of A U.S. Based Wholly- Owned Subsidiary, Pearsanta, Inc	14/23/14	CI
Aditxt, Inc. Forms Adimune, Inc. as Subsidiary	03/23/03	CI
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection	12/22/12	CI
Aditxt Regains Compliance With Nasdaq's Minimum Bid Price Rule	29/22/29	MT
Aditxt to Trade on 1-for-50 Reverse Stock Split Adjusted Basis From Sept. 14	14/22/14	MT
Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials	08/22/08	CI
Aditxt, Inc. cancelled the acquisition of AiPharma from AiPharma Global Holdings LLC.	15/22/15	CI
Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	17/22/17	CI
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore to Accelerate Adoption and Revenue Growth	14/22/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aditxt, Inc.

Equities

ADTX

US0070256047

Highlights

Filters